5Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement.Clinical and Laboratory Standards Institute,Wayne,Pennsylvania:CLSI,2006,1-150..
6Martin GS,Mannino DM,Eaton S,et al.The epidemiology of sepsis in the United States from 1979 through 2000.N Eng J Med,2003,348:1546-1554.
7Wisplingoff H,Bischoff T,Tallent SM,et al.Nosocomial bloodstream infections in US hospital:analysis of 24,179 cases from a prospective nationwide surveillance study.Clin Infect Dis,2004,39:309-317.
4WRODYCKI W. Etiology and course of sepsis in adult patients treated in the Department of Infectious Diseases, Medical University of Lodz-two year observation[J]. Przegl Epidemiol, 2001, 55(Suppl 3): 34-37.
5AYBAR TORKOGLU M, TOPELI ISKIT A. Ventilator- associated pneumonia caused by high risk microorganisms: a matched case-control study[J]. Tuberk Toraks, 2008, 56 (2): 139-149.
6DANCER S J. The effect of antibiotics on methicillin- resistant Staphylococcus aureus [J]. J Antimicrob Chemother, 2008, 61(2): 246-253.
7NIMMO G R, BELL J M, MITCHELL D, et al. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999[J]. Microb Drug Resist, 2003, 9(2): 155-160.
8LINARES J. The VISA/GISA problem: therapeutic implieations[J]. Clin Microbiol Infect, 2001, 7 Suppl 4:8- 15.
9CHANG S, SIEVERT D M, HAGEMAN J C, et al. Infection with vancomyein-resistant Staphylococcus aureus containing the vanA resistance gene[J]. N Engl J Med, 2003, 348(14): 1342-1347.
10Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing;twenty-third informational supplement[S].2013,M100-S23.
